---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-047835"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-04-20T23:59:59+00:00"
generated_at: "2026-06-26T06:14:31.760446+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA board member Lengauer to depart; appoints Timothy Reilly as director

## Summary
- Christoph Lengauer will not stand for re-election at June 30, 2022 annual meeting; departure not due to disagreement.
- Timothy Reilly, Ph.D. appointed to board effective immediately; will serve as Class II director until 2024.
- Reilly previously SVP at Bristol Myers Squibb, currently Chief Development Officer at HotSpot Therapeutics.
- As non-employee director, Reilly receives initial option for 19,200 shares plus annual $40,000 cash retainer.
- Reilly will join Nominating and Corporate Governance Committee on June 30, 2022.

## SEC filing metadata
- accession: 0001104659-22-047835
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-04-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/tm2213066d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-047835
- JSON: https://secwatch.observer/filing/0001104659-22-047835.json
- Plain text: https://secwatch.observer/filing/0001104659-22-047835.txt

## Key facts
- Executive change
  Timothy Reilly was appointed as Director at HOOKIPA Pharma Inc..
  - Action: appointed
  - Role: Director
  source text: On April 15, 2022, the Board appointed Timothy Reilly, Ph.D. as a director of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm
- Executive change
  Christoph Lengauer departed as Director at HOOKIPA Pharma Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: On April 15, 2022, Christoph Lengauer, a member of the board of directors (the “Board”) of HOOKIPA Pharma Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board when his term expires at the Company’s 2022 annual meeting of shareholders on June 30, 2022 (the “2022 Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465922047835/0001104659-22-047835-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.